Fox Run Management’s Acceleron Pharma XLRN Stock Holding History

Fox Run Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,750	Closed	-$220K	–	667
2021 Q2	$220K	Buy	+1,750	New	+$221K	0.2%	260
2019 Q3	–	Sell	-5,685	Closed	-$234K	–	628
2019 Q2	$234K	Buy	+5,685	New	+$235K	0.16%	316
2018 Q2	–	Sell	-9,118	Closed	-$357K	–	990
2018 Q1	$357K	Buy	+9,118	New	+$388K	0.09%	437
2017 Q4	–	Sell	-30,200	Closed	-$1.13M	–	959
2017 Q3	$1.13M	Buy	30,200 +15,900	+111%	+$552K	0.32%	36
2017 Q2	$435K	Sell	14,300 -4,600	-24%	-$133K	0.15%	273
2017 Q1	$500K	Buy	+18,900	New	+$498K	0.2%	183

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Fox Run Management's XLRN Position: Q3 2021 in Review

Fox Run Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 1,750 shares — an estimated $220K sold.

Fox Run Management first reported a position in XLRN in Q1 2017 and held it in 6 quarters. The position peaked at $1.13M in Q3 2017. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Fox Run Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Fox Run Management sold 1,750 Acceleron Pharma shares in Q3 2021, an estimated $220K.
Fox Run Management first reported a position in Acceleron Pharma in Q1 2017 and held it in 6 quarters.
Fox Run Management's Acceleron Pharma position peaked at $1.13M in Q3 2017.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Fox Run Management's 13F filing for Q3 2021, filed 15 Nov 2021.